Screening relatives of people with dilated cardiomyopathy using mobile heart tracing
Tests a mobile AI heart tracing screen in relatives of people with dilated cardiomyopathy.
Plain-language title generated from the registry record
Registry title: Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
Key facts
- Where
- Lancaster, United StatesSee the site
Where in United States
- Lancaster General HospitalLancaster, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lancaster General Hospital
- Trial code
- NCT06688396
- Record updated
- 30 January 2025
- Original description
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.Read full original descriptionShow less
Dilated Cardiomyopathy Detection Using Artificial Intelligence and Screening With Mobile Technology
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.
Inclusion: Male or female age ≥ 18 years; Confirmed diagnosis of non-ischemic DCM determined at the discretion of the treating physician and defined as LVEF ≤ 45% at any time during the clinical course of the patient; Must have at least one living adult FDR; Able to provide informed consent; Male or female age ≥ 18 years who are first-degree relatives of patients with DCM; Proband has provided informed consent; FDR able to provide informed verbal consent; Access to a smartphone or digital tablet with cellular data or Wi-Fi access.
Exclusion: Proband has previously informed FDR to undergo cardiac screening; Previously informed about cardiac screening or has completed cardiac screening by transthoracic echocardiogram (TTE); Congenital structural heart disease; Severe and untreated or untreatable hypertension; Cardiomyopathy due to acute or reversible conditions; examples include tachyarrhythmias, thyroid disorders, iron overload; Ischemic cause of reduced LVEF; evidence of myocardial infarction, inducible ischemia or chest pain on stress testing in absence of coronary angiogram to rule out ischemic disease; history of acute coronary syndromes (STEMI (ST-Elevation Myocardial Infarction), NSTEMI (Non-ST-Elevation Myocardial Infarction) or unstable angina) revascularization or ≥75% stenosis of either left main or Left Anterior Descending (LAD) or ≥75% stenosis of 2 major epicardial vessels on angiogram; Any secondary cause of reduced LVEF such as pregnancy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug; Previously diagnosed with reduced LVEF; DCM attributed to any other secondary form of cardiomyopathy per the investigator's determination; Moderate or greater primary valvular abnormality not due to underlying cardiomyopathy; (CPC Participants only) Home address outside of traveling range; (CPC Participants only) Home address outside of traveling range.